Fax: +514-340-7502
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Cancer Cell Biology
You have full text access to this OnlineOpen article
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
Article first published online: 28 OCT 2003
DOI: 10.1002/ijc.11445
Copyright © 2003 Wiley-Liss, Inc.
Additional Information
How to Cite
Lu, Y., Zi, X. and Pollak, M. (2004), Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer, 108: 334–341. doi: 10.1002/ijc.11445
Publication History
- Issue published online: 21 NOV 2003
- Article first published online: 28 OCT 2003
- Manuscript Accepted: 30 MAY 2003
- Manuscript Revised: 9 MAY 2003
- Manuscript Received: 17 DEC 2002
Funded by
- Canada Breast Cancer Research Initiative
REFERENCES
- 1, , , , . The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11–31.
- 2. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl 4): S3–8.
- 3, . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–37.
- 4, , , , , . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
- 5. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 (Suppl 2): 1–13.
- 6, , . The role of overexpressed HER2 in transformation. Ann Oncol 2001; 12 (Suppl 1): S9–13.
- 7, , , , , , , , , , , , et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–44.
- 8
- 9, , , , , , , , , , , . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.
- 10, , , , . Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852–7.
- 11, . Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 2001; 93: 1830–2.
- 12, , , , . Molecular markers of IGF-I-mediated mitogenesis. Exp Cell Res 1998; 242: 361–72.
- 13, , . The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275: 35893–901.
- 14, . Growth factor–dependent signaling and cell cycle progression. FEBS Lett 2001; 490: 110–6.
- 15, , , , , . Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 1998; 121: 19–26.
- 16, , . Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human–mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731–8.
- 17, , , , , . ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1–Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210–23.
- 18, . Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001; 12 (Suppl 1): S35–41.
- 19, . IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133–7.
- 20, , , . Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050–93.
- 21, . Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472–89.
- 22. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224–8.
- 23, , , . The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrinol Rev 2000; 21: 215–44.
- 24, . Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17: 1343–52.
- 25, . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.
- 26, . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–12.
- 27, . Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–8.
- 28, , , , , , , , , . A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin–Cdk activity in human breast cancer cells. Oncogene 1997; 14: 2283–9.
- 29, , , , , . Enhanced ribosomal association of p27Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997; 272: 7093–8.
- 30, , . Accumulation of the cyclin-dependent kinase inhibitor p27Kip1 and the timing of oligodendrocyte differentiation. EMBO J 1997; 16: 306–17.
- 31, , , , , , , , . Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682–5.
- 32, . Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10–7.Direct Link:
- 33, , , . p27Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene 2001; 20: 3695–702.
- 34, , , . Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000; 275: 24735–9.
- 35, , , . A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998; 58: 1920–9.
- 36, , , . SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193–9.
- 37, , , , . p27Kip1 ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661–4.
- 38, , , , , , , , , , , , et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069–81.
- 39, . Ras activity late in G1 phase required for p27Kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor–stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997; 17: 5348–58.
- 40, . Oncogenic kinase signalling. Nature 2001; 411: 355–65.
- 41. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14: 628–34.
- 42. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855–60.
- 43, , , , , , . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–6.
- 44. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–7.
- 45, . Protean PTEN: form and function. Am J Hum Genet 2002; 70: 829–44.
- 46, , , , , , , , , , , . Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136–44.
- 47, , , , , , . PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145–52.
- 48, , , , , , , , , , , . PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153–60.